Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

pCPA File Number: 21591

Negotiation Status:

Concluded with an LOI

Indication(s):

Cystic Fibrosis, F508del CFTR mutation

Sponsor/Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

CADTH Project Number:

SR0673

pCPA Engagement Letter Issued:

2021-09-17

Negotiation Process Concluded:

2021-09-17